At least six weeks ahead of its assigned PDUFA date, Janssen Research & Development LLC's apalutamide has become the first FDA-approved therapy to treat patients with non-metastatic castration-resistant prostate cancer (nmCRPC), those whose disease has quit responding to medical or surgical treatments that lower testosterone but has yet to spread.